News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,435 Results
Type
Article (40892)
Company Profile (267)
Press Release (680266)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204660)
Career Advice (2022)
Deals (35532)
Drug Delivery (110)
Drug Development (81379)
Employer Resources (173)
FDA (16407)
Job Trends (14943)
News (346368)
Policy (32723)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (141)
Alliances (49575)
ALS (169)
Alzheimer's disease (1664)
Antibody-drug conjugate (ADC) (307)
Approvals (16672)
Artificial intelligence (509)
Autoimmune disease (151)
Automation (38)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (633)
Cancer (4775)
Cardiovascular disease (398)
Career advice (1707)
Career pathing (35)
CAR-T (280)
CDC (44)
Celiac Disease (2)
Cell therapy (739)
Cervical cancer (36)
Clinical research (69536)
Collaboration (1689)
Company closure (4)
Compensation (1152)
Complete response letters (53)
COVID-19 (2709)
CRISPR (87)
C-suite (830)
Cystic fibrosis (143)
Data (6192)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (499)
Diagnostics (6682)
Digital health (47)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (250)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (230)
Earnings (90090)
Editorial (56)
Employer branding (21)
Employer resources (152)
Events (117233)
Executive appointments (967)
FDA (19505)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1459)
Gene editing (192)
Generative AI (43)
Gene therapy (591)
GLP-1 (965)
Government (4655)
Grass and pollen (6)
Guidances (383)
Healthcare (18869)
HIV (58)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (248)
Immuno-oncology (56)
Indications (108)
Infectious disease (2972)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (114)
Intellectual property (245)
Interviews (315)
IPO (16641)
IRA (49)
Job creations (3642)
Job search strategy (1427)
JPM (57)
Kidney cancer (15)
Labor market (84)
Layoffs (546)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (644)
Lymphoma (374)
Machine learning (42)
Management (59)
Manufacturing (790)
MASH (162)
Medical device (13760)
Medtech (13813)
Mergers & acquisitions (19959)
Metabolic disorders (1262)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (313)
Neuropsychiatric disorders (87)
Neuroscience (2885)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4510)
Now hiring (67)
Obesity (592)
Opinion (257)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (223)
Parkinson's disease (279)
Partnered (33)
Patents (489)
Patient recruitment (480)
Peanut (56)
People (58840)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21678)
Phase 2 (30607)
Phase 3 (22797)
Pipeline (5201)
Policy (279)
Postmarket research (2564)
Preclinical (9195)
Press Release (64)
Prostate cancer (236)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (828)
Real estate (5954)
Recruiting (70)
Regulatory (24453)
Reports (52)
Research institute (2386)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (994)
Venture capital (87)
Weight loss (379)
Women's health (89)
Worklife (18)
Date
Today (125)
Last 7 days (643)
Last 30 days (2077)
Last 365 days (29908)
2026 (3165)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (308)
Arkansas (13)
Asia (39206)
Australia (6406)
California (11224)
Canada (3267)
China (1093)
Colorado (476)
Connecticut (472)
Delaware (333)
Europe (84470)
Florida (1672)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (854)
India (64)
Indiana (518)
Iowa (22)
Japan (424)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1375)
Massachusetts (8047)
Michigan (321)
Minnesota (622)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2986)
New Mexico (28)
New York (2956)
North Carolina (1447)
North Dakota (8)
Northern California (5479)
Ohio (331)
Oklahoma (21)
Oregon (41)
Pennsylvania (2267)
Puerto Rico (24)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4366)
Tennessee (174)
Texas (1734)
United States (39788)
Utah (334)
Vermont (1)
Virginia (259)
Washington D.C. (81)
Washington State (915)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,435 Results for "ribomic inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
October 7, 2025
·
5 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Drug Development
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2.
December 5, 2023
·
5 min read
Press Releases
RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort
November 5, 2024
·
5 min read
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Press Releases
Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.
February 10, 2026
·
2 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration
RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).
March 23, 2022
·
5 min read
1 of 72,144
Next
